Catalyst Pharmaceuticals (NASDAQ:CPRX) Issues Earnings Results

Catalyst Pharmaceuticals (NASDAQ:CPRX) posted its quarterly earnings data on Monday. The biopharmaceutical company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15, FiscalAI reports. Catalyst Pharmaceuticals had a return on equity of 36.47% and a net margin of 36.39%.The firm had revenue of $149.39 million for the quarter, compared to analyst estimates of $149.52 million.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock remained flat at $31.15 during trading hours on Monday. The company’s stock had a trading volume of 3,679,869 shares, compared to its average volume of 1,617,562. Catalyst Pharmaceuticals has a 52-week low of $19.05 and a 52-week high of $32.56. The firm has a market capitalization of $3.81 billion, a P/E ratio of 18.43, a price-to-earnings-growth ratio of 0.95 and a beta of 0.72. The company’s fifty day moving average is $25.31 and its 200 day moving average is $23.93.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Parkside Financial Bank & Trust boosted its holdings in shares of Catalyst Pharmaceuticals by 17.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 469 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 55.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 630 shares in the last quarter. E Fund Management Co. Ltd. boosted its holdings in shares of Catalyst Pharmaceuticals by 8.9% during the 2nd quarter. E Fund Management Co. Ltd. now owns 10,656 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 871 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 6.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 16,080 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 927 shares in the last quarter. Finally, California State Teachers Retirement System boosted its holdings in shares of Catalyst Pharmaceuticals by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 99,257 shares of the biopharmaceutical company’s stock valued at $2,154,000 after acquiring an additional 992 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analysts Set New Price Targets

CPRX has been the topic of a number of recent research reports. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $35.00 to $31.50 in a report on Friday. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a report on Thursday. Finally, Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.17.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).